Invesco
INZY

Invesco’s Inozyme Pharma INZY Stock Holding History

Invesco’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,315
Closed -$17.6K – 3808
2025
Q1 		$17.6K Sell
19,315
-592
-3% -$821 ﹤0.01% 3749
2024
Q4 		$55.1K Buy
19,907
+4,484
+29% +$17.1K ﹤0.01% 3683
2024
Q3 		$80.7K Sell
15,423
-981
-6% -$5.09K ﹤0.01% 3646
2024
Q2 		$73.2K Sell
16,404
-1,980
-11% -$9.6K ﹤0.01% 3786
2024
Q1 		$141K Buy
18,384
+541
+3% +$2.97K ﹤0.01% 3709
2023
Q4 		$76K Buy
17,843
+4,795
+37% +$17K ﹤0.01% 3716
2023
Q3 		$54.8K Hold
13,048
– – ﹤0.01% 3790
2023
Q2 		$72.7K Buy
+13,048
New +$77.1K ﹤0.01% 3774

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Invesco's INZY Position: Q2 2025 in Review

Invesco sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 19,315 shares — an estimated $17.6K sold.

Invesco first reported a position in INZY in Q2 2023 and held it in 8 quarters. The position peaked at $141K in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Invesco reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 19,315 Inozyme Pharma shares in Q2 2025, an estimated $17.6K.
  • Invesco first reported a position in Inozyme Pharma in Q2 2023 and held it in 8 quarters.
  • Invesco's Inozyme Pharma position peaked at $141K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.